Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Nature Medicine

Volumn 22, Issue 3, 2016, Pages 270-277

  Ambrogio, Chiara ^a   Gómez López, Gonzalo ^a   Falcone, Mattia ^a,h   Vidal, August ^b,c   Nadal, Ernest ^d   Crosetto, Nicola ^e   Blasco, Rafael B ^a,i   Fernández Marcos, Pablo J ^a   Sánchez Céspedes, Montserrat ^f   Ren, Xiaomei ^g   Wang, Zhen ^g   Ding, Ke ^g   Hidalgo, Manuel ^a   Serrano, Manuel ^a   Villanueva, Alberto ^b,c   Santamaráa, David ^a   Barbacid, Mariano ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Xenopat SL   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e KAROLINSKA INSTITUTE   (Sweden)

^f BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^g GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7RH; CISPLATIN; DASATINIB; DEMCIZUMAB; DISCOIDIN DOMAIN RECEPTOR 1; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NOTCH RECEPTOR; PACLITAXEL; PROTEIN P53; RECEPTOR BLOCKING AGENT; SELUMETINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DDR1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; PROTEIN P21; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENICITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; LUNG ADENOCARCINOMA; LUNG HYPERPLASIA; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; ADENOCARCINOMA; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DASATINIB; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MIDDLE AGED; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, NOTCH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84957717924     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4041     Document Type: Article

References (60)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011
2. Pikor, L.A., Ramnarine, V.R., Lam, S. & Lam, W.L. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 82, 179-189 (2013
3. Meng, D. et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-Analysis. Lung Cancer 81, 1-10 (2013
4. Peters, S., Zimmermann, S. & Adjei, A.A. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat. Rev. 40, 917-926 (2014
5. Gridelli, C. et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat. Rev. 40, 300-306 (2014
6. Jänne, P.A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38-47 (2013
7. Oxnard, G.R., Binder, A. & Jänne, P.A. New targetable oncogenes in non-small-cell lung cancer. J. Clin. Oncol. 31, 1097-1104 (2013
8. Pirker, R. Novel drugs against non-small-cell lung cancer. Curr. Opin. Oncol. 26, 145-151 (2014
9. Reck, M. et al. LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143-155 (2014
10. Gerlinger, M. et al. Cancer: evolution within a lifetime. Annu. Rev. Genet. 48, 215-236 (2014
11. Burrell, R.A. & Swanton, C. The evolution of the unstable cancer genome. Curr. Opin. Genet. Dev. 24, 61-67 (2014
12. Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37, 48-55 (2005
13. Valiathan, R.R., Marco, M., Leitinger, B., Kleer, C.G. & Fridman, R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 31, 295-321 (2012
14. Valencia, K. et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin. Cancer Res. 18, 969-980 (2012
15. Yang, S.H. et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol. Rep. 24, 311-319 (2010
16. Miao, L. et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. Med. Oncol. 30, 626 (2013
17. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007
18. Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003
19. Monti, S., Tamayo, P., Mesirov, J. & Golub, T. Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 91-118 (2003
20. Okayama, H. et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 72, 100-111 (2012
21. Sánchez, M.P. et al. Multiple tyrosine protein kinases in rat hippocampal neurons: isolation of Ptk-3, a receptor expressed in proliferative zones of the developing brain. Proc. Natl. Acad. Sci. USA 91, 1819-1823 (1994
22. Leitinger, B. Discoidin domain receptor functions in physiological and pathological conditions. Int. Rev. Cell Mol. Biol. 310, 39-87 (2014
23. Vogel, W.F., Aszódi, A., Alves, F. & Pawson, T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol. Cell. Biol. 21, 2906-2917 (2001
24. Guerrot, D. et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am. J. Pathol. 179, 83-91 (2011
25. Gao, M. et al. Discovery and optimization of 3-(2-(Pyrazolo[1, 5-A]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J. Med. Chem. 56, 3281-3295 (2013
26. Kim, H.-G., Hwang, S.-Y., Aaronson, S.A., Mandinova, A. & Lee, S.W. DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation. J. Biol. Chem. 286, 17672-17681 (2011
27. Weijzen, S. et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 8, 979-986 (2002
28. Maraver, A. et al. Therapeutic effect of ?-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 22, 222-234 (2012
29. Licciulli, S. et al. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res. 73, 5974-5984 (2013
30. Ito, T. et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 127, 3913-3921 (2000
31. Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012
32. Hegde, G.V. et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci. Transl. Med. 5, 171ra18 (2013
33. Westhoff, B. et al. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA 106, 22293-22298 (2009
34. Hassan, K.A. et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res. 19, 1972-1980 (2013
35. Zheng, Y. et al. A rare population of CD24+ITGB4+Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 24, 59-74 (2013
36. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013
37. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012
38. Li, J. et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 6, 291-299 (2010
39. Crystal, A.S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014
40. Bailis, W., Yashiro-Ohtani, Y. & Pear, W.S. Identifying direct Notch transcriptional targets using the GSI-washout assay. Methods Mol. Biol. 1187, 247-254 (2014
41. Meacham, C.E. & Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-337 (2013
42. Mainardi, S. et al. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 111, 255-260 (2014
43. Desai, T.J., Brownfield, D.G. & Krasnow, M.A. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507, 190-194 (2014
44. Gould, S.E., Junttila, M.R. & de Sauvage, F.J. Translational value of mouse models in oncology drug development. Nat. Med. 21, 431-439 (2015
45. Day, C.-P., Merlino, G. & Van Dyke, T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163, 39-53 (2015
46. Johnson, F.M. et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 4609-4615 (2010
47. Blasco, R.B. et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652-663 (2011
48. Karreth, F.A., Frese, K.K., DeNicola, G.M., Baccarini, M. & Tuveson, D.A. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 1, 128-136 (2011
49. Chetoui, N., El Azreq, M.-A., Boisvert, M., Bergeron, M.-È. & Aoudjit, F. Discoidin domain receptor 1 expression in activated T cells is regulated by the ERK MAP kinase signaling pathway. J. Cell. Biochem. 112, 3666-3674 (2011
50. Yen, W.C. et al. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin. Cancer Res. 18, 5374-5386 (2012
51. Andersson, E.R. & Lendahl, U. Therapeutic modulation of Notch signalling-Are we there yet?. Nat. Rev. Drug Discov. 13, 357-378 (2014
52. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001
53. Hoffman, R.M. Clinically accurate orthotopic mouse models of cancer. Methods Mol. Med. 58, 251-275 (2001
54. Ambrogio, C. et al. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res. 74, 5978-5988 (2014
55. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler Transform. Bioinformatics 26, 589-595 (2010
56. Koboldt, D.C. et al. VarScan2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012
57. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010
58. Smyth, G.K., Michaud, J. & Scott, H.S. Use of within-Array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21, 2067-2075 (2005
59. Rothe, C. et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-Affinity antibodies. J. Mol. Biol. 376, 1182-1200 (2008
60. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010